---
title: Clinical pharmacokinetics and pharmacodynamics of empagliflozin in patients
  with heart failure
date: '2024-06-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38852615/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240610182540&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Plasma concentrations of empagliflozin in patients with
  HF were higher compared to patients with T2D, but the exposure resulting from the
  10 mg dose was still below the exposure resulting from the dose of 25 mg approved
  in patients with T2D. The difference in exposure was attributable to demographic
  characteristics and HF-induced pathophysiological changes. Overall, the results
  confirm 10 mg as the appropriate empagliflozin dose in patients with ...'
disable_comments: true
---
CONCLUSIONS: Plasma concentrations of empagliflozin in patients with HF were higher compared to patients with T2D, but the exposure resulting from the 10 mg dose was still below the exposure resulting from the dose of 25 mg approved in patients with T2D. The difference in exposure was attributable to demographic characteristics and HF-induced pathophysiological changes. Overall, the results confirm 10 mg as the appropriate empagliflozin dose in patients with ...